Examining equity-related eligibility criteria in clinical trials supporting 2022 US drug approvals.
There has been substantial recent attention to the importance of diversity in clinical trials supporting US Food and Drug Administration (FDA) drug approvals, including both Congressional action and FDA guidance. One factor that can contribute to a lack of diverse enrollment is overly strict eligibi...
Saved in:
| Main Authors: | Kathy Sliwinski, Jennifer E Miller, Holly Fernandez Lynch |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0324807 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Overview of drugs approved by the FDA in 2022
by: D. V. Kurkin, et al.
Published: (2023-11-01) -
Leveraging Large Language Models for Clinical Trial Eligibility Criteria Classification
by: Sujan Ray, et al.
Published: (2025-04-01) -
Criteria of eligibility of patients with ischemic cardiomyopathy for revascularization and other surgical procedures
by: N.D. Oryshchyn
Published: (2016-09-01) -
Eligibility Criteria in Advanced Urothelial Cancer Clinical Trials: An Assessment of Modernization and Inclusion
by: Benjamin D. Mercier, et al.
Published: (2025-04-01) -
Lung Cancer Screening Eligibility, Uptake, and Adherence in Puerto Rico, 2022
by: Maira A. Castañeda-Avila, PhD, MS, et al.
Published: (2025-08-01)